NCT01381861View on ClinicalTrials.gov

Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

August 31, 2012

Study Completion Date

December 31, 2013

Conditions
Recurrent Ovarian CancerFallopian Tube CarcinomaPrimary Peritoneal Carcinoma
Interventions
BIOLOGICAL

Carotuximab (TRC105)

Carotuximab (TRC105) 10 mg/kg weekly by intravenous administration on Days 1, 8, 15 and 22 of each 28-day cycle

Trial Locations (7)

10065

Memorial Sloan-Kettering Cancer Center, New York

33401

Palm Beach Cancer Institute, West Palm Beach

35249

University of Alabama at Birmingham, Birmingham

46202

Indiana University-Bren and Melvin Simon Cancer Center, Indianapolis

77230

MD Anderson Cancer Center, Houston

90033

University of Southern California, Los Angeles

92093

University of California, San Diego, La Jolla

All Listed Sponsors
lead

Tracon Pharmaceuticals Inc.

INDUSTRY

NCT01381861 - Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma | Biotech Hunter | Biotech Hunter